Whole-body in-vivo neutron activation analysis in assessing treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.

Naik, R. B.; Gosling, Peter; Price, Christopher P.; Robinson, Brian H.; Dabek, J. T.; Heath, D. A.; James, Helen; Kanis, J. A.; Smith, Rosamund C.

doi:10.1136/bmj.2.6027.79

Cited by 17 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study (21) suggests that increases in whole-body calcium during la-HCC treatment are achieved only in patients in whom biochemical and histological improvements occur during treatment. The present study cannot confirm this.…”

Section: Discussionmentioning

confidence: 99%

Bone Mineral Content in Chronic Renal Failure during Long‐Term Treatment with 1α‐Hydroxycholecalciferol

Madsen

Ølgaard

Ladefoged

1978

Journal of Internal Medicine

View full text Add to dashboard Cite

ABSTRACT. Bone mineral content of the radius (BMC) has been measured by photonabsorptiometry in 22 adults with chronic renal failure before and after on an average 15.4 months of treatment with 1α‐hydroxycholecaiciferol (1α‐HCC). Identical measurements were performed in a control group comprising 26 uremic adults, who did not receive any vitamin D supplements during the study. The BMC was reduced and not significantly different in the two groups of uremic patients at the initial measurement. During treatment with 1α‐HCC the BMC increased significantly in 3 patients, while the total group showed only a small (mean 0.7%), non‐significant increase. In the control group the BMC decreased significantly in 4 patients, while the total group showed a non‐significant decrease (mean 3.5%). However, a comparison of the BMC changes in the two groups revealed a significant difference (p <0.01). The BMC changes in the 1α‐HCC group were uncorrelated to changes in serum calcium, ionized calcium, phosphate, alkaline phosphatases, immunoreactive parathyroid hormone and intestinal calcium abosrption during therapy. The data indicate that cessation of skeletal demineralization in chronic renal failure may be achieved by 1α‐HCC, but re‐mineralization of the skeleton seems to be attainable only in a minority of adult patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Bone Mineral Content in Chronic Renal Failure during Long‐Term Treatment with 1α‐Hydroxycholecalciferol

Madsen

Ølgaard

Ladefoged

1978

Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…More prolonged treatment in similar patients (Nielsen et al, 1975;Davie et al, 1976;Henderson et al, 1976) have also shown radiographic and biochemical improvements. Recent reports have suggested, however, that not all patients with renal bone disease improve after treatment with oc-HCC (Pierides et al, 1976) and that favourable biochemical changes in some patients may be associated with demineralization (Tougaard et al, 1976) and deterioration of bone disease (Naik et al, 1976).…”

Section: Discussionmentioning

confidence: 99%

Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.

Kanis¹,

Henderson²,

Heynen³

et al. 1977

Archives of Disease in Childhood

Self Cite

View full text Add to dashboard Cite

SUMMARY The effects of small oral doses (1-2 tg/day) of loc-hydroxycholecalciferol, given for 1 to 2 years, have been examined in four nondialysed adolescents with chronic renal failure and bone disease. Treatment increased calcium retention and plasma calcium, and decreased plasma levels of alkaline phosphatase, hydroxyproline, and immunoreactive parathyroid hormone. X-ray abnormalities of bone regressed, and 2 patients underwent successful surgical correction of knockknees; bone histology in these 2 was normal at the time of operation. 2 patients developed hypercalcaemia which promptly reversed when lao-hydroxycholecalciferol was withdrawn. In one patient treatment was initially successful, but later there was biochemical, radiographic, and histological evidence of relapse. Long-term treatment of such patients with lac-hydroxycholecalciferol may be effective and facilitate the surgical correction of deformities, but this is not invariable. Toxic effects are similar to those of vitamin D itself, but are more readily reversible.

show abstract

“…3K. 39 In 1972 serum calcium in reference preparations was measured by isotopic dilution coupled with mass spectrometry for reference purposes.I" Whilst ion selective potentiometry has been almost exclusively used to measure ionised calcium, at least one group have displaced protein-bound and complexed calcium by acidification, and meaured total calcium with a neutral carrier based ion-selective electrode."! The diversity of techniques which have been applied to calcium determinations could be a reflection of the dissatisfaction analysts have felt for methods in the past.…”

Section: Comparison Of Methodsmentioning

confidence: 99%

Analytical Reviews in Clinical Biochemistry: Calcium Measurement

Gosling

1986

Ann Clin Biochem

View full text Add to dashboard Cite

Whole-body in-vivo neutron activation analysis in assessing treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.

Cited by 17 publications

References 12 publications

Bone Mineral Content in Chronic Renal Failure during Long‐Term Treatment with 1α‐Hydroxycholecalciferol

Bone Mineral Content in Chronic Renal Failure during Long‐Term Treatment with 1α‐Hydroxycholecalciferol

Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.

Analytical Reviews in Clinical Biochemistry: Calcium Measurement

Contact Info

Product

Resources

About